Syntaxin raises £3m from Abingworth

Syntaxin has obtained its first round funding of £3m from Abingworth Management Ltd, with a further £3m to be invested on achievement of specific milestones. Abingworth and the HPA will be the two largest shareholders. As part of the spin out Syntaxin has acquired rights to an extensive patent portfolio from the HPA that covers the medical application of modified bacterial proteins, including botulinum toxins. In addition, the HPA is transferring to Syntaxin a partnership with Allergan Inc., whereby the technology is licenced to Allergan to develop treatments for pain in return for milestone payments and royalties.

Syntaxin will initially focus on the discovery and development of products for the treatment of pain where, in partnership with Allergan, considerable progress has been achieved. Additional programmes will explore applications of the technology in the treatment of respiratory and metabolic diseases such as chronic obstructive pulmonary disease (COPD), obesity and diabetes.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland